Stock Price Forecast

March 18, 2024


Forecasted Returns

7 Days Predict

30 Days Predict

90 Days Predict


Forecasted Market-Excess Returns

7 Days Predict

30 Days Predict

90 Days Predict

Loading Replimune Group Inc chart...

About the Company

replimune group, inc., a biotechnology company, develops oncolytic immune-gene therapies to treat cancer. it uses its proprietary immulytic platform to design and develop product candidates that are intended to activate the immune system against cancer. the company's lead product candidate is rp1, a selectively replicating version of herpes simplex virus 1, which is in phase i/ii clinical trials for a range of solid tumors; and that is in phase ii clinical trials for patients with cutaneous squamous cell carcinoma. it is also developing rp2, which is in phase i clinical trials for an anti-ctla-4 antibody-like protein in order to block the inhibition of the immune response otherwise caused by ctla-4; and rp3 to express immune-activating proteins that stimulate t cells. replimune group, inc. was founded in 2015 and is headquartered in woburn, massachusetts.

$M

Total Revenue

244

Employees

$508M

Market Capitalization

-2.67

Price/Earning ratio

Fundamental Data and Insider Transactions (Quarterly data) Full Screen

Loading the fundamentals chart...

Latest $REPL News

What Makes Replimune Group, Inc. (REPL) a New Buy Stock

10d ago, source: Zacks.com on MSN

Replimune Group, Inc. (REPL) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is ...

How Much Upside is Left in Replimune Group, Inc. (REPL)? Wall Street Analysts Think 50.17%

7d ago, source: Zacks.com on MSN

Shares of Replimune Group, Inc. (REPL) have gained 16.4% over the past four weeks to close the last trading session at $9.03, but there could still be a solid upside left in the stock if short-term ...

Replimune Group (NASDAQ: REPL)

7d ago, source: The Motley Fool

Replimune Group, Inc. is a clinical-stage biotechnology company, which engages in the development of oncolytic immunotherapy product candidates through immulytic platform. Its product candidates ...

Positive Outlook for Replimune Group with Buy Rating and Increased Price Target Amidst Promising RP1 + Opdivo Therapy Trials

1mon ago, source: Business Insider

Replimune Group (REPL) Company Description: Replimune Group, Inc. is a clinical-stage biotechnology company, which engages in the development of oncolytic immunotherapy product candidates through ...

Replimune Group Inc (REPL) Reports Fiscal Q3 2024 Results and Extends Cash Runway

1mon ago, source: Yahoo Finance

Warning! GuruFocus has detected 2 Warning Sign with REPL. On February 8, 2024, Replimune Group Inc (NASDAQ:REPL) released its 8-K filing, detailing the financial results for the fiscal third ...

Replimune Group Inc 7R8

5d ago, source: Morningstar

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Replimune Group Inc (REPL)

26d ago, source: Investing

Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company’s proprietary tumor-directed oncolytic ...

Replimune Group Inc REPL

1mon ago, source: Morningstar

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Replimune Group Inc (REPL)

1mon ago, source: Investing

Investing.com - Replimune (NASDAQ: REPL) reported third quarter EPS of $-0.77, $0.12 better than the analyst estimate of $-0.89. Revenue for the quarter came in at $0.00 versus the ...

Latest Neutral (free) Forecasts

STRONG BUY BUY NEUTRAL SELL STRONG SELL ALL

Loading the latest forecasts...

My Portfolio

Loading your portfolio...